NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/17/2026
Back to search
Official data from USPTO
ROME THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
56
Latest update
02/17/2026
Trademark type
Combined
Nice classes
42
Filing date
12/23/2021
Registration date
02/17/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/17/2026
Last transaction
02/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/27/2020
First use in commerce
04/27/2020
Drawing code
5
Owner type
03
Owner location
Boston, MA, US
Examiner
HERR, JENNA FRANCES
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "ROME" in black with a yellow shadow connected to the left side of the letter "O" on top of the word "THERAPEUTICS" in black. The letter "R" in "ROME" is incomplete and does not include the left, vertical segment of the letter.
Holders and representatives
Holders
ROME Therapeutics, Inc.
Representatives
GLENN A GUNDERSEN DECHERT LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical research and development in the field of cancer and autoimmune disease; pharmaceutical drug development and discovery services in the field of cancer and autoimmune disease; scientific research in the field of pharmaceuticals; providing scientific research information in the field of pharmaceuticals; none of the foregoing relating to gastrointestinal issues
Publications
History of USPTO decisions and trademark events.
56 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
02/17/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/26/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/26/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/22/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/21/2026
EX2G
SOU EXTENSION 2 GRANTED
01/21/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/31/2025
IUAF
USE AMENDMENT FILED
07/30/2025
EXT2
SOU EXTENSION 2 FILED
07/30/2025
EISU
TEAS STATEMENT OF USE RECEIVED
07/30/2025
EX1G
SOU EXTENSION 1 GRANTED
07/30/2025
EXT1
SOU EXTENSION 1 FILED
07/30/2025
EEXT
SOU TEAS EXTENSION RECEIVED
07/30/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/04/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/10/2024
PUBO
PUBLISHED FOR OPPOSITION
12/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/04/2024
EXPT
EXPARTE APPEAL TERMINATED
10/15/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/15/2024
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
09/06/2024
GNSF
SUBSEQUENT FINAL EMAILED
09/06/2024
CFRC
SUBSEQUENT FINAL REFUSAL WRITTEN
09/06/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/15/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/15/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
07/15/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/03/2024
GNSL
LETTER OF SUSPENSION E-MAILED
05/03/2024
CNSL
SUSPENSION LETTER WRITTEN
05/03/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/03/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/26/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
01/26/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/29/2023
GNSL
LETTER OF SUSPENSION E-MAILED
12/29/2023
CNSL
SUSPENSION LETTER WRITTEN
12/29/2023
EXPI
EX PARTE APPEAL-INSTITUTED
12/06/2023
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
12/06/2023
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
12/06/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
12/05/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
08/28/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
08/28/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/25/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/25/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/25/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/05/2023
GNFR
FINAL REFUSAL E-MAILED
06/05/2023
CNFR
FINAL REFUSAL WRITTEN
06/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/13/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/12/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/12/2022
GNRT
NON-FINAL ACTION E-MAILED
10/12/2022
CNRT
NON-FINAL ACTION WRITTEN
10/12/2022
DOCK
ASSIGNED TO EXAMINER
09/27/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/30/2021
NWAP
NEW APPLICATION ENTERED
12/27/2021
Continuous trademark protection
Get notified about every new filing that threatens ROME THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.